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Abstract
Rationale:  Early evaluation of the burden of disease that COVID-19 may produce in a com-
munity is critical to appropriately allocate resources for COVID-19 prevention and treatment. 
Objective:  The primary objective of this study is to define the incidence, epidemiology, and 
clinical outcomes of patients with COVID-19 in the Louisville,  Kentucky and southern Indiana 
region (Kentuckiana) of the USA. 
Methods:  This will be a retrospective observational study of patients in the Kentuckiana region 
with the diagnosis of COVID-19. 
Background and Significance
The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 
2020. [1] The virus that causes COVID-19 is SARS-CoV-2. It is expected that SARS-
CoV-2 will reach global spread and will infect a significant number of the global popu-
lation. The declaration of a pandemic refers primarily to the capability of SARS-CoV-2 
to spread from person to person at a global level, but the declaration of pandemic is not 
related to the severity of SARS-CoV-2. The burden of patients with COVID-19 may vary 
from region to region. This variability is primarily due to the mutations that SARS-CoV-2 
will accumulate as the virus moves through the population. When the virus mutates, it 
undergoes small changes in its genome. A common pattern of evolution for viral infec-
tions is that as the virus mutates, it may have the capability to spread more efficient-
ly from person to person, and at the same time, the strain may become less aggressive, 
which results in better outcomes in patients with the disease. Even though this is the 
most likely evolution of a virus, we do not know if the new mutations of SARS-CoV-2 will 
produce a virus more virulent or less virulent. At the present time, there are different 
patterns of burden of disease originating in China [2], Italy [3], and Germany [4]. Why 
the clinical outcomes of patients with COVID-19 in these regions are different is unclear, 
but different viral mutations may partially explain the clinical outcomes.
Because of the above, it is clear that it will be difficult to predict the burden of COVID-19 
in the city of Louisville, Kentucky and the surrounding area, regularly referred to as the 
Kentuckiana region, based on burden of disease from other regions. Defining burden of 
disease as soon as possible after SARS-CoV-2 arrives in the region is critical to properly 
inform public health authorities for development of effective preventive strategies, and 
healthcare professionals so they are able to appropriately and safely manage and treat-
ment patients with COVID-19.
In an attempt to identify early burden of disease in Kentuckiana, the primary objective 
of this study is to define the incidence, epidemiology, and clinical outcomes of patients 
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diagnosed with COVID-19 in Kentuckiana.
Objectives
Primary Objectives
1. To define the incidence, epidemiology, and clinical outcomes of patients in Kentuckiana diagnosed with COVID-19.
Secondary Objectives
1. To evaluate incidence of COVID-19 in special populations. 
2. To evaluate better inform Public Health authorities of local COVID-19 activity.
3. To define areas of the community where surveillance activities should be increased. 
4. To rapidly disseminate the new knowledge gained by this project.
Methods
Study Design and Subjects
The Burden of COVID-19 study will be a retrospective cohort study of all patients in the Kentuckiana region with di-
agnosis of COVID-19, and has been approved by the University of Louisville Institutional Review Board as #20-0257. 
Inclusion and Exclusion Criteria
A patient will be defined as having COVID-19 when the virus SARS-CoV-2 was identified in a clinical specimen using 
Polymerase Chain Reaction (PCR). All patients with diagnosis of COVID-19 will be evaluated. The study will have no 
exclusion criteria.
Incidence Calculations
The monthly COVID-19 incidence rates per 100,000 adults will be estimated for:  unique patients (unadjusted and 
age-adjusted), total hospitalizations, unique patients by various age groups, unique patients by comorbid conditions 
and smoking status, as well as for white and black/African American races. 
Geospatial Epidemiology
To define specific hot areas with high density of COVID-19 in Kentuckiana, initially the geomasked location of each 
patient’s home address will be obtained through the US Census Bureau website. A Kernel Density heatmap will be cre-
ated. Kuldorff ’s Spatial Scan Statistic will be used to calculate significant areas of risk for COVID-19. Choropleth maps 
will be created to compare census tract-level demographics and the spatial distribution of COVID-19 cases. 
Mortality
All-cause mortality for all COVID-19 patients will be evaluated at 30-days, 6-months, and 1-year after diagnosis. Mor-
tality data will be obtained from the Kentucky Department for Public Health Office of Vital Statistics.
Scientific Advisory Board
A scientific advisory board has been established with leaders from Kentuckiana health care systems. The board has 
the following objectives: 1) To provide feedback for improvement of the Burden of COVID-19 study; 2) To support the 
dissemination of information. Regular meetings will be held by the principal investigator and members of the scientific 
advisory board.
Preliminary Studies
The principal investigator, Dr. Julio Ramirez, has vast experience in development and implementation of studies eval-
uating burden of particular infectious diseases.
Dr. Ramirez is the Chief of the Division of Infectious Diseases and Director of the Center of Excellence for Research in 
Infectious Diseases (ceridlouisville.org). He has led multiple surveillance programs in the State of Kentucky, including 
the Severe Influenza Pneumonia Surveillance (SIPS) Project. SIPS was funded by the Department of Homeland Secu-
rity. [5] He was also funded by the Centers for Disease Control and Prevention to study the role of oseltamivir in hospi-
talized patients with influenza in the city of Louisville. This was done in collaboration of CERID with all adult hospitals 
in Louisville. [6] More recently, Pfizer Pharmaceuticals sponsored CERID to perform a population-based study of all 
hospitalized adult patients in the city of Louisville to define the burden of community-acquired pneumonia. Data from 
this study were used to estimate the burden of pneumonia in the United States. [7] The successes of these studies led to 
the selection of CERID as the North American Center of Excellence for Vaccine Epidemiology, funded by Pfizer. This 
is the first such center in the world, and recognizes the unique infrastructure and capabilities of UofL CERID (Center 
of Excellence announcement).
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/4 3
ULJRI Defining the Burden of COVID-19 in the Kentuckiana Area: Incidence, Epidemiology & Clinical Outcomes of Patients with COVID-19
Project Coordinating Center
The Burden of COVID-19 study will be coordinated by the Center of Excellence for Research in Infectious Diseases 
(CERID). The current structure of CERID is depicted in Figure 1. The activities related to this project for each of the 
CERID units are as follows:
1. Data Management Unit: generate the data collection form and the REDCap database for this project.
2. Implementation Unit: responsible for data collection, and data entry into the REDCap database. 
3. Laboratory Unit: No activity related to this retrospective study. 
4. Biostatistics Unit: will be responsible for periodic and real-time analysis of incidence, epidemiological, and clinical 
outcomes data.
5. Medical Writing Unit: will support the generation of manuscripts. 
6. Peer-Review Journals Unit: will facilitate rapid publication of new knowledge.
7. Informatics Unit: will support the data management unit and implementation unit in regard to computer and data-
base maintenance.
8. Community Outreach Unit: will be responsible for maintaining open lines of communication with community leaders 
and coordinating activities of the Advisory Board.
9. University Outreach Unit: will be responsible for maintaining open lines of communication with UofL leaders and will 
work with the Community Outreach Unit to coordinate the activities of the Advisory Board.
10. Marketing Unit: will collaborate with investigators to develop education and response communications.
Figure 1. Structure of the Project Coordinating Center.
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Protection of Human Subjects
All patient information will be entered into REDCap databases, which are HIPAA-compliant. All surveillance informa-
tion is considered protected health information and standard data safety processes will be followed.
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